Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGE NYSE:BHVN NYSE:QGEN NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$134.130.0%$110.79$34.34▼$134.46$8.30B0.321.68 million shs338,478 shsBHVNBiohaven$13.61-1.2%$13.34$7.48▼$18.57$2.04B1.282.64 million shs440,095 shsQGENQiagen$42.00-0.7%$38.43$32.53▼$57.81$8.65B0.642.43 million shs672,923 shsTGTXTG Therapeutics$54.24-1.1%$49.65$25.28▼$59.30$8.30B1.62.19 million shs1.31 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics-0.08%-0.02%+1.22%+63.56%+238.30%BHVNBiohaven-5.10%-11.35%-12.88%+49.61%+5.02%QGENQiagen+2.71%+4.00%+7.11%+25.44%-21.47%TGTXTG Therapeutics-1.58%+1.71%-1.72%+63.40%+52.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$134.130.0%$110.79$34.34▼$134.46$8.30B0.321.68 million shs338,478 shsBHVNBiohaven$13.61-1.2%$13.34$7.48▼$18.57$2.04B1.282.64 million shs440,095 shsQGENQiagen$42.00-0.7%$38.43$32.53▼$57.81$8.65B0.642.43 million shs672,923 shsTGTXTG Therapeutics$54.24-1.1%$49.65$25.28▼$59.30$8.30B1.62.19 million shs1.31 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics-0.08%-0.02%+1.22%+63.56%+238.30%BHVNBiohaven-5.10%-11.35%-12.88%+49.61%+5.02%QGENQiagen+2.71%+4.00%+7.11%+25.44%-21.47%TGTXTG Therapeutics-1.58%+1.71%-1.72%+63.40%+52.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 2.24Hold$121.25-9.60% DownsideBHVNBiohaven 2.67Moderate Buy$21.6358.91% UpsideQGENQiagen 2.36Hold$43.343.18% UpsideTGTXTG Therapeutics 2.44Hold$58.507.85% UpsideCurrent Analyst Ratings BreakdownLatest BHVN, TGTX, QGEN, and APGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/27/2026TGTXTG Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$55.00 ➝ $86.007/17/2026APGEApogee Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/15/2026QGENQiagen TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold7/14/2026QGENQiagen Berenberg BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy ➝ Hold$45.507/13/2026TGTXTG Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$70.00 ➝ $77.007/7/2026TGTXTG Therapeutics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderperform$17.00 ➝ $20.007/6/2026TGTXTG Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.006/29/2026BHVNBiohaven Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$11.006/29/2026BHVNBiohaven Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform$12.00 ➝ $11.006/26/2026BHVNBiohaven Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/25/2026QGENQiagen Kepler Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetHold$38.60(Data available from 7/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$13.23 per shareN/ABHVNBiohavenN/AN/AN/AN/A$0.39 per shareN/AQGENQiagen$2.09B4.14$3.48 per share12.07$17.89 per share2.35TGTXTG Therapeutics$616.29M13.47$2.73 per share19.90$4.08 per share13.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$255.84M-$4.33N/AN/AN/AN/A-32.64%-31.25%8/10/2026 (Estimated)BHVNBiohaven-$738.82M-$5.67N/AN/AN/AN/A-866.46%-137.99%8/10/2026 (Estimated)QGENQiagen$424.88M$1.9121.9216.034.1019.16%14.40%8.40%8/5/2026 (Confirmed)TGTXTG Therapeutics$447.18M$2.8618.9618.451.4065.95%88.73%43.44%8/3/2026 (Estimated)Latest BHVN, TGTX, QGEN, and APGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026APGEApogee Therapeutics-$1.10N/AN/AN/A$10.00 millionN/A8/10/2026Q2 2026BHVNBiohaven-$0.77N/AN/AN/A$0.49 millionN/A8/5/2026Q2 2026QGENQiagen$0.60N/AN/AN/A$527.65 millionN/A8/3/2026Q2 2026TGTXTG Therapeutics$0.3057N/AN/AN/A$229.77 millionN/A5/11/2026Q1 2026APGEApogee Therapeutics-$1.0658-$1.06+$0.0058-$1.06N/AN/A5/7/2026Q1 2026QGENQiagen$0.54$0.54N/A$0.33$496.15 million$492.32 million5/6/2026Q1 2026TGTXTG Therapeutics$0.23$0.12-$0.11$0.12$200.33 million$204.92 million5/4/2026Q1 2026BHVNBiohaven-$0.86-$0.88-$0.02-$0.88$0.27 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/ABHVNBiohavenN/AN/AN/AN/AN/AQGENQiagen$0.350.83%N/A18.32%N/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ALatest BHVN, TGTX, QGEN, and APGE DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/11/2026QGENQiagenannual$0.350.9%7/7/20267/7/20267/14/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A32.5932.59BHVNBiohaven1.877.417.41QGENQiagen0.493.212.57TGTXTG Therapeutics1.285.815.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%BHVNBiohaven88.78%QGENQiagen70.00%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics24.30%BHVNBiohaven13.80%QGENQiagen9.00%TGTXTG Therapeutics8.87%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9161.88 million46.84 millionOptionableBHVNBiohaven239150.56 million129.78 millionOptionableQGENQiagen5,654206.07 million187.53 millionOptionableTGTXTG Therapeutics290153.08 million139.51 millionOptionableBHVN, TGTX, QGEN, and APGE HeadlinesRecent News About These CompaniesTG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business UpdateJuly 29 at 7:30 AM | globenewswire.comTG Therapeutics (TGTX) to Report Q2 Results: Wall Street Expects Earnings GrowthJuly 27 at 11:03 AM | zacks.comTG Therapeutics (TGTX) to Post Earnings on MondayJuly 27 at 5:55 AM | marketbeat.comFifth Third Bancorp Grows Stock Position in TG Therapeutics, Inc. $TGTXJuly 26 at 3:35 AM | marketbeat.comHsbc Holdings PLC Has $3.56 Million Stock Holdings in TG Therapeutics, Inc. $TGTXJuly 25, 2026 | marketbeat.comKnott David M Jr Has $2.99 Million Position in TG Therapeutics, Inc. $TGTXJuly 24, 2026 | marketbeat.comPrincipal Financial Group Inc. Sells 182,261 Shares of TG Therapeutics, Inc. $TGTXJuly 22, 2026 | marketbeat.comKuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law FirmJuly 21, 2026 | prnewswire.comKuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law FirmJuly 16, 2026 | globenewswire.comAnalysts Conflicted on These Healthcare Names: Biogen (BIIB) and TG Therapeutics (TGTX)July 16, 2026 | theglobeandmail.comBank of America Securities Keeps Their Sell Rating on TG Therapeutics (TGTX)July 15, 2026 | theglobeandmail.comHC Wainwright Forecasts Reduced Earnings for TG TherapeuticsJuly 15, 2026 | marketbeat.comTG Therapeutics (TGTX) Gets a Buy from H.C. WainwrightJuly 15, 2026 | theglobeandmail.comHC Wainwright Cuts Earnings Estimates for TG TherapeuticsJuly 14, 2026 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Recommendation of "Moderate Buy" from BrokeragesJuly 14, 2026 | marketbeat.comTG Therapeutics (TGTX) Gains as Its Key Drug Exceeded ExpectationsJuly 13, 2026 | insidermonkey.comHC Wainwright Forecasts Strong Price Appreciation for TG Therapeutics (NASDAQ:TGTX) StockJuly 13, 2026 | marketbeat.comHsbc Holdings PLC Raises Stake in TG Therapeutics, Inc. $TGTXJuly 10, 2026 | marketbeat.comTG Therapeutics (TGTX) Starts Phase 2 Briumvi TrialJuly 9, 2026 | finance.yahoo.comTG Therapeutics (TGTX) Stock May Still Be Cheap Despite New Trial NewsJuly 9, 2026 | finance.yahoo.comCan TG Therapeutics' (TGTX) Schizophrenia Trial Meaningfully Redefine BRIUMVI’s Role Beyond Multiple Sclerosis?July 8, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBHVN, TGTX, QGEN, and APGE Company DescriptionsApogee Therapeutics NASDAQ:APGE$134.13 -0.04 (-0.03%) As of 01:34 PM Eastern This is a fair market value price provided by Massive. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Biohaven NYSE:BHVN$13.61 -0.16 (-1.18%) As of 01:34 PM Eastern This is a fair market value price provided by Massive. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Qiagen NYSE:QGEN$42.00 -0.28 (-0.65%) As of 01:34 PM Eastern This is a fair market value price provided by Massive. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.TG Therapeutics NASDAQ:TGTX$54.24 -0.63 (-1.15%) As of 01:34 PM Eastern This is a fair market value price provided by Massive. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom’s $200 Billion Samsung Deal Shows How Costly the AI Memory Race Has Become Carrier Earnings Could Send the Stock to a New All-Time High Amazon’s Satellite Push Raises the Stakes for SpaceX and AST SpaceMobile 3 Refiners Benefiting From Oil Volatility and Tight Fuel Supply NVIDIA’s OpenAI Backstop Puts AI Financing Risk in Focus Insiders Sell, Institutions Buy: The AI Trade Is Getting More Interesting D-Wave’s AT&T Deal Shows Quantum Computing Is Moving Beyond Theory Welltower at 52-Week Highs—But Analysts Believe There's More to Come Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
